Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18043765 | 1.00 | LMNA (0.34) | LMNAMAPK1 | |
| SCHEMBL2175295 | 0.80 | MAPK1 (0.36) | LMNAMAPK1 | |
| SCHEMBL31455454 | 0.71 | ATM (0.34) | LMNA | |
| SCHEMBL2172483 | 0.68 | CHRM2 (0.34) | LMNAMAPK1 | |
| SCHEMBL2174224 | 0.68 | MAPK1 (0.30) | MAPK1 | |
| SCHEMBL19759347 | 0.66 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL23216562 | 0.64 | GRM5 (0.34) | LMNA | |
| SCHEMBL23216564 | 0.64 | GRM5 (0.34) | LMNA | |
| SCHEMBL2172712 | 0.63 | HPGD (0.48) | LMNA | |
| SCHEMBL30984671 | 0.62 | USP2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440958-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2016-09-13 | — | — | US | disclosed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | LMNA 2321/4885MAPK1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.